Brandon Capital, an Australasian life science venture capital firm, has co-led a $68 million series A financing of Pheon Therapeutics (Pheon).
Other leading life sciences investors Forbion and Atlas Venture co-led the round, with participation from seed investor Research Corporation Technologies (RCT).
Jonathan Tobin, Partner and head of Brandon Capital’s London office, takes on the role of Chairman of Pheon’s board of directors.
This new investment, Brandon’s largest into a European based company to date, will enable Pheon to advance its lead Antibody-Drug Conjugate (ADC) programme to clinical proof-of-concept and establish a pipeline of novel ADCs.
